NEU neuren pharmaceuticals limited

Ann: 2022 Annual Report to shareholders, page-3

  1. 1,639 Posts.
    lightbulb Created with Sketch. 371
    Based on the below from the AR it looks like they are thinking ahead in relation to NNZ-2591 partnership. Its a bullish statement. I wonder if they are in discussions with any parties at the moment as i recall Jon did mention they had interest.


    NNZ-2591 has the potential to generate larger value for shareholders than trofinetide. We are now carefully evaluating all options to maximize this value, preparing actively for Phase 3 studies while remaining receptive to partnering alternatives.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.83
Change
-0.270(2.06%)
Mkt cap ! $1.607B
Open High Low Value Volume
$13.20 $13.36 $12.83 $2.850M 217.5K

Buyers (Bids)

No. Vol. Price($)
4 384 $12.82
 

Sellers (Offers)

Price($) Vol. No.
$12.84 359 7
View Market Depth
Last trade - 13.43pm 16/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.